• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多基因风险评分对2型糖尿病预测家族史的附加价值:来自“我们所有人”研究数据库的结果

Additive Value of Polygenic Risk Score to Family History for Type 2 Diabetes Prediction: Results From the All of Us Research Database.

作者信息

Drzymalla Emily, Raffield Laura, Kolor Katherine, Koyama Alain, Moonesinghe Ramal, Pavkov Meda E, Spracklen Cassandra N, Khoury Muin J

机构信息

Division of Blood Disorders and Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA.

Department of Genetics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.

出版信息

Diabetes Care. 2025 Feb 1;48(2):212-219. doi: 10.2337/dc24-1537.

DOI:10.2337/dc24-1537
PMID:39841967
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11770167/
Abstract

OBJECTIVE

The goal of this study was to assess the additive value of considering type 2 diabetes (T2D) polygenic risk score (PRS) in addition to family history for T2D prediction.

RESEARCH DESIGN AND METHODS

Data were obtained from the All of Us (AoU) research database. First-degree T2D family history was self-reported on the personal family history health questionnaire. A PRS was constructed from 1,289 variants identified from a large multiancestry genome-wide association study meta-analysis for T2D. Logistic regression models were run to generate odds ratios (ORs) and 95% CIs for T2D. All models were adjusted for age, sex, and BMI.

RESULTS

A total of 109,958 AoU research participants were included in the analysis. The odds of T2D increased with 1 SD PRS (OR 1.75; 95% CI 1.71-1.79) and positive T2D family history (OR 2.32; 95% CI 2.20-2.43). In the joint model, both 1 SD PRS (OR 1.69; 95% CI 1.65-1.72) and family history (OR 2.06; 95% CI 1.98-2.15) were significantly associated with T2D, although the ORs were slightly attenuated. Predictive models that included both the PRS and family history (area under the curve [AUC] 0.794) performed better than models including only family history (AUC 0.763) or the PRS (AUC 0.785).

CONCLUSIONS

In predicting T2D, inclusion of a T2D PRS in addition to family history of T2D (first-degree relatives) added statistical value. Further study is needed to determine whether consideration of both family history and a PRS would be useful for clinical T2D prediction.

摘要

目的

本研究的目的是评估在2型糖尿病(T2D)预测中,除家族史外,考虑T2D多基因风险评分(PRS)的附加价值。

研究设计与方法

数据来自“我们所有人”(AoU)研究数据库。一级亲属的T2D家族史通过个人家族史健康问卷自行报告。PRS由从一项针对T2D的大型多血统全基因组关联研究荟萃分析中鉴定出的1289个变异构建而成。运行逻辑回归模型以生成T2D的比值比(OR)和95%置信区间(CI)。所有模型均根据年龄、性别和体重指数进行了调整。

结果

共有109958名AoU研究参与者纳入分析。T2D的患病几率随PRS增加1个标准差(OR 1.75;95% CI 1.71 - 1.79)以及T2D家族史呈阳性(OR 2.32;95% CI 2.20 - 2.43)而增加。在联合模型中,PRS增加1个标准差(OR 1.69;95% CI 1.65 - 1.72)和家族史(OR 2.06;95% CI 1.98 - 2.15)均与T2D显著相关,尽管OR值略有减弱。同时包含PRS和家族史的预测模型(曲线下面积[AUC] 0.794)比仅包含家族史(AUC 0.763)或PRS(AUC 0.785)的模型表现更好。

结论

在预测T2D时,除T2D家族史(一级亲属)外纳入T2D PRS增加了统计价值。需要进一步研究以确定同时考虑家族史和PRS对临床T2D预测是否有用。

相似文献

1
Additive Value of Polygenic Risk Score to Family History for Type 2 Diabetes Prediction: Results From the All of Us Research Database.多基因风险评分对2型糖尿病预测家族史的附加价值:来自“我们所有人”研究数据库的结果
Diabetes Care. 2025 Feb 1;48(2):212-219. doi: 10.2337/dc24-1537.
2
Genome-Wide Polygenic Risk Score Predicts Incident Type 2 Diabetes in Women With History of Gestational Diabetes.全基因组多基因风险评分预测有妊娠糖尿病史的女性发生 2 型糖尿病的风险。
Diabetes Care. 2024 Sep 1;47(9):1622-1629. doi: 10.2337/dc24-0022.
3
The Clinical Usefulness of a Glaucoma Polygenic Risk Score in 4 Population-Based European Ancestry Cohorts.青光眼多基因风险评分在4个欧洲血统人群队列中的临床实用性。
Ophthalmology. 2025 Feb;132(2):228-237. doi: 10.1016/j.ophtha.2024.08.005. Epub 2024 Aug 14.
4
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
5
Polygenic Risk Score-Based Association Analysis Identifies Genetic Comorbidities Associated with Age-Related Hearing Difficulty in Two Independent Samples.基于多基因风险评分的关联分析确定了与两个独立样本中年龄相关性听力困难相关的遗传共病。
J Assoc Res Otolaryngol. 2024 Aug;25(4):387-406. doi: 10.1007/s10162-024-00947-0. Epub 2024 May 23.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
7
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
8
Polygenic risk-based prediction of heart failure in young patients with atrial fibrillation: an analysis from UK Biobank.基于多基因风险的年轻房颤患者心力衰竭预测:来自英国生物银行的分析。
Europace. 2025 Jul 1;27(7). doi: 10.1093/europace/euaf104.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
10
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎:系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.

引用本文的文献

1
Multi-ancestry polygenic risk scores for the prediction of type 2 diabetes and complications in diverse ancestries.用于预测不同血统人群2型糖尿病及其并发症的多血统多基因风险评分。
medRxiv. 2025 Jul 23:2025.07.21.25331778. doi: 10.1101/2025.07.21.25331778.

本文引用的文献

1
Characterizing apparent treatment resistant hypertension in the United States: insights from the All of Us Research Program.美国显性难治性高血压的特征分析:来自“我们所有人”研究计划的见解
J Am Med Inform Assoc. 2024 Dec 1;31(12):2899-2907. doi: 10.1093/jamia/ocae227.
2
The validity of pathology codes for biopsy-confirmed kidney disease in the Danish National Patobank.丹麦国家病理库中经活检确诊的肾病病理编码的有效性。
Clin Kidney J. 2024 Jul 9;17(8):sfae203. doi: 10.1093/ckj/sfae203. eCollection 2024 Aug.
3
Measuring social determinants of health in the All of Us Research Program.
测量“全民研究计划”中的健康社会决定因素。
Sci Rep. 2024 Apr 16;14(1):8815. doi: 10.1038/s41598-024-57410-6.
4
Genetic drivers of heterogeneity in type 2 diabetes pathophysiology.2 型糖尿病病理生理学异质性的遗传驱动因素。
Nature. 2024 Mar;627(8003):347-357. doi: 10.1038/s41586-024-07019-6. Epub 2024 Feb 19.
5
Genomic data in the All of Us Research Program.全美国研究计划中的基因组数据。
Nature. 2024 Mar;627(8003):340-346. doi: 10.1038/s41586-023-06957-x. Epub 2024 Feb 19.
6
Identifying top ten predictors of type 2 diabetes through machine learning analysis of UK Biobank data.通过对英国生物库数据的机器学习分析,确定 2 型糖尿病的十大预测因子。
Sci Rep. 2024 Jan 24;14(1):2102. doi: 10.1038/s41598-024-52023-5.
7
Risk Factors and Treatment Trends for Onychomycosis: A Case-Control Study of Onychomycosis Patients in the All of Us Research Program.甲癣的危险因素及治疗趋势:“我们所有人”研究项目中甲癣患者的病例对照研究
J Fungi (Basel). 2023 Jun 29;9(7):712. doi: 10.3390/jof9070712.
8
Clinical utility of polygenic risk scores: a critical 2023 appraisal.多基因风险评分的临床效用:2023年的批判性评估
J Community Genet. 2023 Oct;14(5):471-487. doi: 10.1007/s12687-023-00645-z. Epub 2023 May 3.
9
A polygenic and family risk score are both independently associated with risk of type 2 diabetes in a population-based study.基于人群的研究表明,多基因风险评分和家族风险评分均与 2 型糖尿病风险独立相关。
Sci Rep. 2023 Mar 23;13(1):4805. doi: 10.1038/s41598-023-31496-w.
10
The clinical application of polygenic risk scores: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).多基因风险评分的临床应用:美国医学遗传学与基因组学学会(ACMG)的一份要点声明
Genet Med. 2023 May;25(5):100803. doi: 10.1016/j.gim.2023.100803. Epub 2023 Mar 15.